

CLAIMS

What is claimed is:

- 5 1. A method of treating Down Syndrome, said method comprising:
treating a person having Down Syndrome with an effective amount of a compound selected from the group consisting of phenserine, (+)-9-N-phenylcarbinol esroline, a pharmaceutically acceptable salt thereof, and combinations thereof.
- 10 2. The method according to claim 1, wherein the compound is a pharmaceutically acceptable salt of phenserine selected from the group consisting of the tartrate, phosphate, and fumarate salt.
- 15 3. The method according to claim 1, wherein the effective amount ranges from 0.001 gram to 1 gram per kilogram of body mass of the person.
4. The method according to claim 1, wherein the compound comprises (+)-9-N-phenylcarbinol esroline and pharmaceutically acceptable salts thereof.
- 20 5. The method according to claim 1, wherein the compound comprises phenserine or pharmaceutically acceptable salts thereof.
6. A method for treating Down Syndrome in a person, said method comprising:
administering a pharmaceutical composition to the person comprising an effective amount of phenserine, (+)-9-N-phenylcarbinol esroline, pharmaceutically acceptable salts thereof, or combinations thereof as the effective ingredient.
- 25 7. The method according to claim 6, wherein the pharmaceutically acceptable salt is selected from the group consisting of the tartrate, phosphate, and fumarate salt.
- 30 8. The method according to claim 7, wherein the effective amount ranges from 0.001 gram to 1 gram per kilogram of body weight of the person.

THIS PAGE BLANK (USPTO)

9. The method according to claim 6, wherein the pharmaceutical composition compound comprises (+)9-N-phenylcarbinol esroline and pharmaceutically acceptable salts thereof.
10. The method according to claim 6, wherein the pharmaceutical composition comprises 5 phenserine and pharmaceutically acceptable salts thereof.
11. Use of an effective amount of a compound selected from the group consisting of phenserine, (+) 9-N-phenylcarbinol esroline, a pharmaceutically acceptable salt thereof, and combinations thereof for the manufacture of a medicament for the treatment of Down 10 Syndrome.
12. Use of claim 11, wherein the compound is a pharmaceutically acceptable salt of phenserine selected from the group consisting of the tartrate, phosphate, and fumarate salts.
13. Use of claim 11, wherein the compound is a pharmaceutically acceptable salt of (+) 9-N-phenylcarbinol selected from the group consisting of the tartrate, phosphate, and fumarate salts.
14. Use of claim 12, wherein the effective amount is between 5 to 60 mg per 20 administration.
15. Use of claim 11, wherein the medicament is formulated to be administered once or twice a day.
16. Use of claim 11, wherein the compound is (+) 9-N-phenylcarbinol esroline or a pharmaceutically acceptable salt thereof.
17. Use of claim 16, wherein the compound is a pharmaceutically acceptable tartrate salt 30 of (+) 9-N-phenylcarbinol esroline.
18. Use of claim 11, wherein the compound comprises phenserine.

19. Use of claim 18, wherein the compound is a pharmaceutically acceptable tartrate salt of phenserine.
20. A method of manufacturing a pharmaceutical preparation for the treatment of Down Syndrome or preventing or delaying complications associated with Down Syndrome, said method comprising incorporating phenserine, (+)-phenserine, pharmaceutically acceptable salts thereof, or combinations thereof into said pharmaceutical preparation.